- Home
- INBX vs AVIR Comparison
INBX vs AVIR Comparison
Compare INBX & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBX
- AVIR
- Stock Information
- Founded
- INBX 2010
- AVIR 2012
- Country
- INBX United States
- AVIR United States
- Employees
- INBX N/A
- AVIR N/A
- Industry
- INBX Biotechnology: Pharmaceutical Preparations
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- INBX Health Care
- AVIR Health Care
- Exchange
- INBX Nasdaq
- AVIR Nasdaq
- Market Cap
- INBX 345.8M
- AVIR 290.4M
- IPO Year
- INBX 2020
- AVIR 2020
- Fundamental
- Price
- INBX $27.52
- AVIR $3.14
- Analyst Decision
- INBX Hold
- AVIR Hold
- Analyst Count
- INBX 2
- AVIR 1
- Target Price
- INBX N/A
- AVIR $6.00
- AVG Volume (30 Days)
- INBX 113.1K
- AVIR 270.5K
- Earning Date
- INBX 11-13-2025
- AVIR 11-06-2025
- Dividend Yield
- INBX N/A
- AVIR N/A
- EPS Growth
- INBX N/A
- AVIR N/A
- EPS
- INBX N/A
- AVIR N/A
- Revenue
- INBX $1,400,000.00
- AVIR N/A
- Revenue This Year
- INBX N/A
- AVIR N/A
- Revenue Next Year
- INBX N/A
- AVIR N/A
- P/E Ratio
- INBX N/A
- AVIR N/A
- Revenue Growth
- INBX N/A
- AVIR N/A
- 52 Week Low
- INBX $10.81
- AVIR $2.46
- 52 Week High
- INBX $30.23
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- INBX 58.56
- AVIR 36.73
- Support Level
- INBX $27.51
- AVIR $3.10
- Resistance Level
- INBX $30.23
- AVIR $3.33
- Average True Range (ATR)
- INBX 1.47
- AVIR 0.14
- MACD
- INBX -0.09
- AVIR -0.03
- Stochastic Oscillator
- INBX 54.53
- AVIR 6.47
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).